Directors’ / PDMR Dealing
13 September 2024
Futura Medical plc
("Futura" or the "Company")
Directors' / PDMR Dealing
Futura Medical plc (AIM: FUM), the consumer healthcare company behind Eroxon, that specialises in the development and global commercialisation of innovative and clinically proven sexual health products, announces that it has received notice to exercise options from James Barder, CEO and Ken James, executive Head of R&D to exercise 500,000 options over ordinary shares of 0.2 pence in the Company ("Ordinary Shares").
The following options have been exercised:
Director | Number of Options exercised | Status | Exercise price | Total number of Options held following exercise |
James Barder | 250,000 | Unapproved | 30.50p | |
James Barder | 50,000 | EMI | 15.50p | 3,660,927 |
Ken James | 200,000 | EMI | 30.50p | 3,455,955 |
James Barder has sold 250,000 Ordinary Shares the proceeds of which will be used to satisfy the tax liability and the exercise of 50,000 options with an exercise price of 15.50p, these shares will be retained by James. In addition, Ken James has sold 200,000 Ordinary Shares.
Following these transactions James Barder's interests in Ordinary Shares is 1,470,972 Ordinary Shares, representing approximately 0.5% of the Company's issued share capital. Ken James' interests in Ordinary Shares of 299,581 Ordinary Shares representing approximately 0.1% of the Company's issued share capital remains unchanged.
450,000 options with an exercise price of 30.50p would lapse on 30 September 2024, if not exercised.
Further disclosures are contained in the tables below.
Total Voting Rights
Following the issue of 500,000 Ordinary Shares under the Company's existing block listings to satisfy the exercise of options, for the purposes of the FCA's Disclosure and Transparency Rules, the Company's total issued share capital at the date of this announcement is 302,363,641 Ordinary Shares.
Since the Company currently holds no shares in treasury, the total number of voting rights in the Company is 302,363,641 and this figure may therefore be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.
ENDS
Contacts:
Futura Medical plc
| James Barder Chief Executive Officer Angela Hildreth Finance Director and COO
| +44 (0)1483 685 670 www.futuramedical.com
|
Panmure Liberum Nominated Adviser and Broker
| Emma Earl, Will Goode, Mark Rogers (Corporate Finance) Rupert Dearden (Corporate Broking) | +44 (0)20 3100 2000
|
| ||
Stifel Nicolaus Europe Limited Joint Broker
| Alan Selby Ben Maddison
| +44 (0)207 710 7600
|
| ||
Alma Strategic Communications | Rebecca Sanders-Hewett Sam Modlin Will Ellis Hancock | +44 (0)20 3405 0205 |
Notes to Editors:
Futura Medical plc (AIM: FUM) is the developer of innovative sexual health products, including lead product Eroxon. Our core strength lies in our research, development and commercialisation of topically delivered gel formulations in sexual health products.
Eroxon, Futura's clinically proven lead product, has been developed for the treatment of Erectile Dysfunction ("ED"). The highly differentiated product, which is the only topical gel treatment for ED available over the counter and helps men get an erection in ten minutes, addresses significant unmet needs in the ED market.
ED impacts 1 in 5 men globally across all adult age brackets, with approximately half of all men over 40 experiencing ED and 25% of all new diagnoses being in men under 40.
Futura has distribution partners in place in a number of major consumer markets including Haleon in the US, the largest market for ED in the world, and Cooper Consumer Health in Europe. Eroxon has been nominated for a number of healthcare industry awards and has won two to-date.
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||||||
a) | Name | James Barder | ||||||||||||
2 | Reason for the notification | |||||||||||||
a) | Position/status | Chief Executive Officer | ||||||||||||
b) | Initial notification/Amendment | Initial notification | ||||||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
a) | Name | Futura Medical plc | ||||||||||||
b) | LEI | 21380053QLT46UNV2303 | ||||||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares at 0.2p each
GB0033278473 | ||||||||||||
b) | Nature of the transaction | 1. Exercise of options with exercise price of 30.50p 2. Disposal of 250,000 ordinary shares following exercise 3. Exercise of 50,000 options with exercise price of 15.50p
| ||||||||||||
c) | Price(s) and volume(s)
|
| ||||||||||||
d) | Aggregated information - Aggregated volume - Price | 1. 250,000 2. 250,000 3. 65,000
1. £76,250.00 2. £101,657.00 3. £7,750
| ||||||||||||
e) | Date of the transaction | 12 September 24 | ||||||||||||
f) | Place of the transaction | 1. Outside a trading venue 2. XLON 3. Outside a trading venue | ||||||||||||
1 | Details of the person discharging managerial responsibilities/person closely associated | ||||||||||
a) | Name | Ken James | |||||||||
2 | Reason for the notification | ||||||||||
a) | Position/status | Executive Director | |||||||||
b) | Initial notification/Amendment | Initial notification | |||||||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||||||||
a) | Name | Futura Medical plc | |||||||||
b) | LEI | 21380053QLT46UNV2303 | |||||||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||||||||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary shares at 0.2p each
GB0033278473 | |||||||||
b) | Nature of the transaction | 1. Exercise of options with exercise price of 30.50p 2. Disposal of 200,000 ordinary shares following exercise
| |||||||||
c) | Price(s) and volume(s)
|
| |||||||||
d) | Aggregated information - Aggregated volume - Price | 1. 200,000 2. 200,000
1. £61,000.00 2. £81,325.60
| |||||||||
e) | Date of the transaction | 12 September 2024 | |||||||||
f) | Place of the transaction | 1. Outside a trading venue 2. XLON | |||||||||
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.